The use of ACE inhibitors decreases hematocrit levels, which lowers the circulating angiotensin II, further inhibiting the growth of erythroid progenitors and N-acetyl-seryl-aspartyl-proline catabolism, causing anemia in the first 3 months of therapy. Here, ACE is linked to anemia (phenotype).